Pfizer Inc.’s Tukysa, when given as part of the initial treatment for an advanced form of breast cancer, delayed tumor growth ...

While new late-stage data point to some liver toxicity signals, analysts at BMO Capital Markets said Tukysa’s efficacy ...

(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) Dec ...

Pfizer's oral HER2 inhibitor Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive ...

Tukysa added to Herceptin and Perjeta improved progression-free survival versus placebo in HER2-positive metastatic breast ...

Tukysa, a tyrosine kinase inhibitor by Pfizer, delays disease progression in HER2-positive metastatic breast cancer. In a late-stage trial with 654 patients, it improved progression-free survival by 8 ...

Pfizer announces Tukysa added to first-line maintenance therapy extends median PFS by over 8 months in patients with HER2+ metastatic breast cancer: New York Friday, December 12, ...

Pfizer has rolled out detailed trial data suggesting Tukysa could be part of a new first-line treatment to delay the progression of HER2-positive breast cancer. | Pfizer has rolled out detailed trial ...

Adding the targeted drug Tukysa (tucatinib) to Herceptin (trastuzumab) and the chemotherapy Xeloda (capecitabine) lengthens life and time until disease progression in patients, without decreasing ...

Two years after its approval, Seagen’s potential blockbuster Tukysa is off to a promising start as a treatment for breast cancer. Now the Seattle-area biotech is hoping to expand its use to colorectal ...

-- Results of Phase 3 HER2CLIMB-02 trial featured in an oral presentation and official press program at the 2023 San Antonio Breast Cancer Symposium -- BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc.

Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor ...